<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">RANITIDINE HYDROCHLORIDE</span><br/>(ra-nye'te-deen)<br/><span class="topboxtradename">Zantac, </span><span class="topboxtradename">Zantac EFFERdose, </span><span class="topboxtradename">Zantac GELdose, </span><span class="topboxtradename">Zantac-75<br/></span><b>Classifications:</b> <span class="classification">gastrointestinal agent</span>; <span class="classification">antisecretory (h<sub>2</sub>-receptor antagonist)</span><br/><b>Prototype: </b>Cimetidine<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>75 mg, 150 mg, 300 mg tablets; 25 mg, 150 mg effervescent tablets; 150 mg, 300 mg capsules; 15 mg/mL syrup; 0.5 mg/mL, 25 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Potent anti-ulcer drug that competitively and reversibly inhibits histamine action at H<sub>2</sub>-receptor sites on parietal cells, thus blocking gastric acid secretion. Indirectly reduces pepsin secretion but appears to
         have minimal effect on fasting and postprandial serum gastrin concentrations or secretion of gastric intrinsic factor or mucus.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Blocks daytime and nocturnal basal gastric acid secretion stimulated by histamine and reduces gastric acid release in response
         to food, pentagastrin, and insulin. Shown to inhibit 50% of the stimulated gastric acid secretion.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Short-term treatment of active duodenal ulcer; maintenance therapy for duodenal ulcer patient after healing of acute ulcer;
         treatment of gastroesophageal reflux disease; short-term treatment of active, benign gastric ulcer; treatment of pathologic
         GI hypersecretory conditions (e.g., Zollinger-Ellison syndrome, systemic mastocytosis, and postoperative hypersecretion);
         heartburn.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to ranitidine; acute porphyria; OTC administration in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Hypersensitivity to H<sub>2</sub>-blockers; hepatic and renal dysfunction; renal failure; PKU; pregnancy (category B), infants 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Duodenal Ulcer, Gastric Ulcer, Gastroesophageal Reflux</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 150 mg b.i.d. or 300 mg h.s. <span class="rdroute">IV</span> 50 mg q68h; 150300 mg/24 h by continuous infusion<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 45 mg/kg/d divided q812h (max: 6 mg/kg/d or 300 mg/d) <span class="rdroute">IM/IV</span> 24 mg/kg/d divided q68h; 0.10.125 mg/kg/h by continuous infusion<br/><span class="rdage">Infant:</span> <span class="rdroute">PO</span> 2 wk, 2 mg/kg/d divided q12h <span class="rdroute">IV</span> 1.5 mg/kg/d divided q12h or 0.04 mg/kg/h by continuous infusion<br/><br/><span class="indicationtitle">Duodenal Ulcer, Maintenance Therapy</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 150 mg h.s.<br/><br/><span class="indicationtitle">Pathologic Hypersecretory Conditions</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 150 mg b.i.d. up to 6.3 g/d <span class="rdroute">IV</span> 50 mg q68h<br/><br/><span class="indicationtitle">Heartburn</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 75150 mg b.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with or without food; simultaneous administration does not appear to reduce absorption or serum concentrations.</li>
<li>Administer adjunctive antacid treatment 2 h before or after drug.</li>
<li>Store tablets in light-resistant, tightly capped container at 15°30° C (59°86° F) in a dry
            place.
         </li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li> 				Note: Does not need to be diluted. 			</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p> 				Note: Verify correct IV concentration and rate of infusion for infants and children with physician. 			</p>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype"> Direct:</span>  Dilute 50 mg NS, D5W, RL, or other compatible IV solution to a total volume of 20 mL.  <span class="methodtype">Intermittent:</span> Dilute 50 mg in 50100 mL of NS, D5W, RL, or other compatible IV solution.  <span class="methodtype">Continuous:</span> Dilute total daily dose in 250 mL of NS, D5W, RL, or other compatible IV solution. Final concentration should be <img src="../images/special/lesserorequal.gif"/>2.5
                  mg/mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give at a rate of 4 mL/min or 20 mL over not less than 5 min.  <span class="methodtype">Intermittent:</span> Give over 1530 min.  <span class="methodtype">Continuous:</span> Give over 24 h.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> <b>Amphotericin B,</b> <b>atracurium,</b> <b>cefamandole,</b> <b>cefazolin,</b> <b>cefoxitin,</b> <b>ceftazidime,</b> <b>cefuroxime,</b> <b>clindamycin,</b> <b>chlorpromazine,</b> <b>diazepam,</b> <b>ethacrynic acid,</b> <b>hydroxyzine,</b> <b>methotrimeprazine,</b> <b>midazolam,</b> <b>nalbuphine,</b> <b>pentobarbital,</b> <b>phenobarbital,</b> <b>phytonadione</b> <span class="classification">opium alkaloids</span>, <b>phenobarbital.</b> <span class="incompattype">Y-site:</span> <b>Amphotericin B cholesteryl complex,</b> <b>methotrimeprazine,</b> <b>midazolam,</b> <span class="classification">opium alkaloids</span>, <b>phenobarbital.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Schedule dose to coincide with end of treatment if patient is having hemodialysis.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, malaise, dizziness, somnolence, insomnia, vertigo, mental confusion, agitation, depression, hallucinations in older
      adults. <span class="typehead">CV:</span> Bradycardia (with rapid IV push). <span class="typehead">GI:</span> Constipation, nausea, abdominal pain, diarrhea. <span class="typehead">Skin:</span> Rash. <span class="typehead">Hematologic:</span> Reversible decrease in WBC count, thrombocytopenia. <span class="typehead">Body as a Whole:</span> Hypersensitivity reactions, <span class="speceff-life">anaphylaxis</span> (rare). 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Ranitidine may produce slight elevations in <span class="alt">serum creatinine</span> (without concurrent increase in <span class="alt">BUN</span>); (rare) increases in <span class="alt">AST,</span> <span class="alt">ALT,</span> <span class="alt">alkaline phosphatase,</span> <span class="alt">LDH,</span> and total <span class="alt">bilirubin.</span> Produces false-positive tests for <span class="alt">urine protein</span> with <span class="alt">Multistix</span> (use <span class="alt">sulfosalicylic acid</span> instead).
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> may reduce absorption of <b>cefpodoxime,</b> <b>cefuroxime,</b> <b>delavirdine,</b> <b>ketoconazole,</b> <b>itraconazole.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Incompletely absorbed from GI tract (50% reaches systemic circulation). <span class="typehead">Peak:</span> 23 h PO. <span class="typehead">Duration:</span> 812 h. <span class="typehead">Distribution:</span> Distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine, with some excreted in feces. <span class="typehead">Half-Life:</span> 23 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Potential toxicity results from decreased clearance (elimination) and therefore prolonged action; greatest in the older adult
            patients or those with hepatic or renal dysfunction.
         </li>
<li>Lab tests: Periodic liver functions. Monitor creatinine clearance if renal dysfunction is present or suspected. When clearance
            is 
         </li><li>Be alert for early signs of hepatotoxicity (though low and thought to be a hypersensitivity reaction): jaundice (dark urine,
            pruritus, yellow sclera and skin), elevated transaminases (especially ALT) and LDH.
         </li>
<li>Long-term therapy may lead to vitamin B<sub>12</sub> deficiency.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li> 							Note: Long duration of action provides ulcer pain relief that is maintained through the night as well as the day. 						</li>
<li>Be aware that even if symptomatic relief is provided by ranitidine, this should not be interpreted as absence of gastric malignancy.
            Follow-up examinations will be scheduled after therapy is discontinued.
         </li>
<li>Adhere to scheduled periodic laboratory checkups during ranitidine treatment.</li>
<li>Do not supplement therapy with OTC remedies for gastric distress or pain without physician's advice (e.g., Mylanta II reduces
            ranitidine absorption).
         </li>
<li>Do not smoke; research shows smoking decreases ranitidine efficacy and adversely affects ulcer healing.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>